{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:23:07Z","timestamp":1793658187155,"version":"4.5.1"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Endovasc Ther"],"abstract":"<jats:p>As the most severe manifestation of peripheral arterial disease, patients with chronic limb-threatening ischemia (CLTI) are at significant risk for adverse outcomes, such as amputation and mortality. A standard endovascular therapy for below the knee (BTK) intervention, percutaneous transluminal angioplasty (PTA), has shown high rates of restenosis and frequent re-interventions. Alternative technologies, such as drug-eluting stents (DES) and drug-coated balloons, have not consistently demonstrated superiority over PTA and have not received US regulatory approval. Esprit BTK, recently approved by the Food and Drug Administration (FDA), is a novel drug-eluting resorbable scaffold (DRS) designed for treatment of infrapopliteal artery disease in patients with CLTI. The Esprit BTK DRS has shown superior efficacy and non-inferior safety compared with PTA. This technology is an evolution of the coronary Absorb bioresorbable vascular scaffold (BVS) sought to improve upon the limitations of metallic DES. Coronary use of Absorb BVS provided both technical and clinical insights that informed the design and adaptation of bioresorbable scaffolds for infrapopliteal applications. Findings from the ABSORB coronary clinical trials and Absorb BTK studies for treating infrapopliteal atherosclerotic disease, including procedural and implantation best practices, were incorporated and implemented into the development of the Esprit BTK DRS and LIFE-BTK randomized controlled trial protocol.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Clinical Impact<\/jats:title>\n                    <jats:p>The Esprit BTK drug-eluting resorbable scaffold is the first Food and Drug Administration (FDA)-approved bioresorbable device for infrapopliteal artery disease in patients with chronic limb-threatening ischemia (CLTI). In the LIFE-BTK randomized trial, it demonstrated superior efficacy and non-inferior safety versus angioplasty. Designed with thinner struts and optimized for BTK anatomy, Esprit BTK incorporates learnings from Absorb bioresorbable vascular scaffold and emphasizes intravascular imaging and procedural best practices. These innovations address clinical challenges, offering clinicians a novel, evidence-based alternative to percutaneous transluminal angioplasty with the potential to improve long-term outcomes in patients with CLTI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15266028251399144","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T07:25:56Z","timestamp":1765869956000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["From Coronary Arteries to Lower Limbs: Advances in Drug-Eluting Bioresorbable Scaffolds for Treating Chronic Limb-Threatening Ischemia"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8170-4960","authenticated-orcid":false,"given":"Andrew","family":"Holden","sequence":"first","affiliation":[{"name":"Department of Interventional Radiology, Auckland City Hospital, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5611-6991","authenticated-orcid":false,"given":"Ramon","family":"Varcoe","sequence":"additional","affiliation":[{"name":"Prince of Wales Hospital, University of New South Wales, Randwick, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"DeRubertis","sequence":"additional","affiliation":[{"name":"NewYork-Presbyterian\/Weill Cornell Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector M.","family":"Garcia-Garcia","sequence":"additional","affiliation":[{"name":"MedStar Washington Hospital Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Khatib","sequence":"additional","affiliation":[{"name":"First Coast Cardiovascular Institute, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Metzger","sequence":"additional","affiliation":[{"name":"OhioHealth Riverside Methodist Hospital, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2871-3689","authenticated-orcid":false,"given":"Prakash","family":"Krishnan","sequence":"additional","affiliation":[{"name":"The Mount Sinai Hospital, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Cawich","sequence":"additional","affiliation":[{"name":"Arkansas Heart Hospital, Little Rock, AR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0883-0829","authenticated-orcid":false,"given":"Steven","family":"Kum","sequence":"additional","affiliation":[{"name":"Changi General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Popiel","sequence":"additional","affiliation":[{"name":"Abbott Vascular, Santa Clara, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rapoza","sequence":"additional","affiliation":[{"name":"Abbott Vascular, Santa Clara, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Jones-McMeans","sequence":"additional","affiliation":[{"name":"Abbott Vascular, Santa Clara, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Parikh","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021539"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.25270\/jic\/20.00530"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01039-9"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509038"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.4101"},{"key":"e_1_3_2_7_2","volume-title":"Long-Term Outcomes of Absorb BVS Final 5-Year Results From the ABSORB Clinical Trial Program","author":"Power DA.","year":"2024","unstructured":"Power DA. Long-Term Outcomes of Absorb BVS Final 5-Year Results From the ABSORB Clinical Trial Program. Washington, DC: Cardiovascular Research Technologies; 2024."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602818799735"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13019-022-01812-y"},{"key":"e_1_3_2_10_2","volume-title":"FDA Investigating Increased Rate of Major Adverse Cardiac Events Observed in Patients Receiving Abbott Vascular\u2019s Absorb GT1 Bioresorbable Vascular Scaffold (BVS)\u2014Letter to Health Care Providers","author":"Maisel W.","year":"2017","unstructured":"Maisel W. FDA Investigating Increased Rate of Major Adverse Cardiac Events Observed in Patients Receiving Abbott Vascular\u2019s Absorb GT1 Bioresorbable Vascular Scaffold (BVS)\u2014Letter to Health Care Providers. Silver Spring, MD: U.S. Food and Drug Administration; 2017."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-23-0877"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-16-00974"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.08.020"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X20977907"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602818799736"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.29327"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602817698935"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17050735"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.310275"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.12.2995"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jscai.2023.100964"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305637"},{"key":"e_1_3_2_23_2","volume-title":"Wound assessment and outcomes in the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit BTK\u2122 Drug-Eluting Resorbable Scaffold","author":"Kolluri R.","year":"2023","unstructured":"Kolluri R. Wound assessment and outcomes in the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit BTK\u2122 Drug-Eluting Resorbable Scaffold. Las Vegas, NV: Vascular Interventional Advances; 2023."},{"key":"e_1_3_2_24_2","volume-title":"Two-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the EspritTM BTK Drug-Eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions","author":"DeRubertis BG.","year":"2024","unstructured":"DeRubertis BG. Two-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the EspritTM BTK Drug-Eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions. Las Vegas, NV: Vascular Interventional Advances; 2024."},{"key":"e_1_3_2_25_2","first-page":"52","article-title":"Implantation Technique for Bioresorbable Scaffolds Device description and patient\/lesion selection with the Absorb BVS","author":"Jiang Ming Fam M","year":"2017","unstructured":"Jiang Ming Fam M, van Geuns R-J. Implantation Technique for Bioresorbable Scaffolds Device description and patient\/lesion selection with the Absorb BVS. Cardiac Interventions Today, January\/February 2017:52\u201356.","journal-title":"Cardiac Interventions Today"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.002518"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.09.608"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-18-00607"},{"issue":"3","key":"e_1_3_2_29_2","first-page":"199","article-title":"Bioresorbable coronary scaffolds are ready for a comeback: pros and cons","volume":"19","author":"Stone GW","year":"2023","unstructured":"Stone GW, Biensock SW, Neumann FJ. Bioresorbable coronary scaffolds are ready for a comeback: pros and cons. Eurointervention. 2023;19(3):199\u2013202.","journal-title":"Eurointervention"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001251"},{"key":"e_1_3_2_31_2","article-title":"The MLD MAX OCT algorithm: an imaging-based workflow for percutaneous coronary intervention","volume":"100","author":"Shlofmitz E","year":"2022","unstructured":"Shlofmitz E, Croce K, Bezerra H, et al. The MLD MAX OCT algorithm: an imaging-based workflow for percutaneous coronary intervention. Catheter Cardiovasc Interv. 2022;100(suppl 1):S7\u2013S13.","journal-title":"Catheter Cardiovasc Interv"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-022-01643-2"},{"key":"e_1_3_2_33_2","volume-title":"Extrapolation of LIFE-BTK to Real-World Practice","author":"Rapoza RJ.","year":"2024","unstructured":"Rapoza RJ. Extrapolation of LIFE-BTK to Real-World Practice. Washington, DC: Cardiovascular Research Technologies; 2024."}],"container-title":["Journal of Endovascular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028251399144","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15266028251399144","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028251399144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:32:05Z","timestamp":1777498325000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15266028251399144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":32,"alternative-id":["10.1177\/15266028251399144"],"URL":"https:\/\/doi.org\/10.1177\/15266028251399144","relation":{},"ISSN":["1526-6028","1545-1550"],"issn-type":[{"value":"1526-6028","type":"print"},{"value":"1545-1550","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"article-number":"15266028251399144"}}